

## **The changing treatment landscape for HR+HER2-mBC patient with CDKi**

Dejan Juric, M.D.

Director/ Termeer Center for Targeted Therapies & Program Director of the  
Investigational Cancer Therapeutics Program, Mass General Hospital Cancer Center  
Physician/ Medicine (Hematology/Oncology) at Massachusetts General Hospital  
Boston, U.S.A.

Given the recent year updates of the significant overall survival data (MONALEESA2,3,7 series and MONARCH2) from the CDK4/6 inhibitors, the treatment landscape for HR+HER2-mBC is no longer only fight for progression free survival improvement, but also overall survival improvement, even including, chemotherapy-free survival, and time to chemotherapy in MONALEESA series. In recent updated of MONALEESA-2 & MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus AI or fulvestrant to reach over 5 years median overall survival data, and to add more than a year difference in overall survival time vs AI/fulvestrant alone. In this session, we will review all the overall survival data and discuss about how it will possible influence the treatment landscape changing of current clinical practice.